2019
Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy
Gill JS, Formica RN, Levitsky J. Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. Journal Of The American Society Of Nephrology 2019, 30: 1778-1780. PMID: 31570540, PMCID: PMC6779353, DOI: 10.1681/asn.2019070726.Peer-Reviewed Original Research
2018
Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients
Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Current Opinion In Organ Transplantation 2018, 23: 257-263. PMID: 29432255, DOI: 10.1097/mot.0000000000000504.Peer-Reviewed Original ResearchConceptsViremic donorsHepatitis CWaitlist mortalityHepatitis C viremic donorsEarly trial dataHCV-negative recipientsTransplantation of graftsHepatitis C therapySolid organ transplantsSolid organ transplantationUtilization of graftsFormal clinical trialsNet overall reductionGraft utilizationNonviremic recipientsTransplant recipientsC therapyNegative patientsAntiviral therapyNegative recipientsTransplantation ratesClinical trialsOrgan poolDonor organsOrgan transplantation
2017
Response to: HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?
Levitsky J, Formica R. Response to: HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals? American Journal Of Transplantation 2017, 17: 2988. PMID: 28858416, DOI: 10.1111/ajt.14478.Peer-Reviewed Original ResearchThe American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation
Levitsky J, Formica R, Bloom R, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O’Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. American Journal Of Transplantation 2017, 17: 2790-2802. PMID: 28556422, DOI: 10.1111/ajt.14381.Peer-Reviewed Original ResearchMeSH KeywordsHepacivirusHepatitis CHumansOrgan TransplantationSocieties, MedicalTissue DonorsViremiaConceptsSolid organ transplantationOrgan transplantationHepatitis C viremic donorsHepatitis C virus infectionEnd-stage organ diseaseHCV-viremic organsHCV-viremic patientsProspective research protocolC virus infectionChronic HCV infectionAmerican SocietyViremic donorsViremic organsViremic recipientsHCV infectionHepatitis CTransplant waitlistMeeting of expertsOrgan diseaseVirus infectionOrgan transplantsYoung donorsAntiviral agentsConsensus conferenceTransplantation
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response